Linked Life Data

18324369

Source:http://linkedlifedata.com/resource/pubmed/id/18324369

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-3-7
pubmed:abstractText
Designated radiopharmaceuticals labelled with the prominent positron-emitter (18)F can be defined as molecular imaging probes for the examination of cardiovascular diseases at the cellular and subcellular level. Such molecular imaging agents representing radioindicators or radiotracers offer the opportunity to non-invasively trace their path and fate in the living organism by the scintigraphic technique, positron emission tomography (PET). The glucose analogue [(18)F]FDG is a widespread PET tracer and one of the earliest examples of a PET molecular imaging probe feasible to in vivo visualise glucose utilisation by a metabolic trapping mechanism. This short review is focussed on selected established (18)F-labelled PET tracers as well as (18)F-labelled radioligands in development that show the potential of being probes for the in vivo molecular imaging of proteins relevant in cardiovascular diseases such as receptors (i.e. beta-Adrenoceptors), transporters (i.e. NET and VMAT) and proteases (i.e. MMPs).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0300-8428
pubmed:author
pubmed:issnType
Print
pubmed:volume
103
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
131-43
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
(18)F-labelled cardiac PET tracers: selected probes for the molecular imaging of transporters, receptors and proteases.
pubmed:affiliation
Dept. of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Str. 33, 48149, Münster, Germany. kopka@uni-muenster.de
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't